Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
In our 30+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
Dr. Novack’s work on educating ophthalmologists, optometrists and patients about the safety of over-the-counter (OTC) medications was highlighted in the University of California, Davis, Department of Ophthalmology & Vision Sciences newsletter, Envision. In this article, he discusses product recalls in 2023 and 2024. Patients who use medications prescribed by their
Dr. Novack published the lead article in the June 2024 issue of the American Journal of Ophthalmology. In this article, he showed a time line of key U.S. FDA registration and the availability of ocular hypotensive drugs (i.e., drugs that decrease elevated intraocular pressure) to patients and their doctors. He
Dr. Novack was cited in an article in the New York Times on 4 April 2024 regarding the safety of ophthalmic medications. He noted that eye-care products have a higher risk of health harm because they’re applied directly to the eye. Also, that manufacturing and storing these products has to